Why experts saw Cano Health’s bankruptcy coming from a mile away

The latest stories trending on MedCity News.

Editor's Pick

Top Story Why Experts Saw Cano Health's Bankruptcy Coming From A Mile Away Cano Health filed for bankruptcy this week — about three years after going public $4.4 billion SPAC merger. The industry reacted without surprise, with experts calling the bankruptcy a direct result of mismanagement, a quixotic growth strategy and poor market selection. Sponsored Content Lower BMI, Raise ROI: How Physician Practices Can Boost Revenues with a Turnkey Weight Management Program Presented by Build My Health and MedCity News The webinar, scheduled for March 6 at 2pm ET and sponsored by Build My Health, will discuss several topics related to weight management including: an overview of GLP-1 weight loss medication, automation in a subscription-based weight management program, and the rise of provider-to-consumer (PTC) models. Learn how to help patients lose weight as well as opportunity to generate $250K+ in monthly recurring revenue! INVEST 2024 Value = Networking Connections, partnerships, funding, investments, plus top notch speakers and content - all of this and more is what you can expect from INVEST 2024. Hurry and save with the Super Early Bird Rate, but only until Feb 16th, then the price goes up. Register Now

Featured News

StartUPDATES: New Developments for Healthcare Startups Check out news from Health Wildcatters, Rivia Health, Apella, and more. Upsized Kyverna IPO Gets $319M to Bring CAR T-Therapy to Autoimmune Diseases Cell therapies were first validated in cancer, but Kyverna Therapeutics aims to show they're safe enough for autoimmune diseases. The biotech plans to deploy its IPO cash across clinical trials in lupus nephritis, multiple sclerosis, systemic sclerosis, and myasthenia gravis. Papa Launches Programs To Address Health-Related Social Needs, Improve Star Ratings Companion care company Papa has created two programs for health plans: one that addresses social drivers of health and one that aims to improve health plans' star ratings. BioNTech Pact and Stock Sale Infuse Autolus With $600M for Its Cell Therapies Autolus will apply the capital to its CAR T-cell therapy currently under FDA review in cancer and in early clinical development in lupus. Meanwhile, BioNTech will gain access to Autolus's cell therapy manufacturing assets as well as technologies that could support the R&D of in vivo therapies and antibody drug conjugates. Five Ways AI Will Impact Clinical Trials This Year The integration of AI technologies holds promise for enhancing outreach efforts, streamlining recruitment processes, and addressing long-standing barriers and biases that hinder diversity and inclusion in clinical trials.

Resources

Affordable Surgical Robots In this MedCity Pivot Podcast episode, Anne Osdoit, CEO of Moon Surgical and Partner at European venture capital firm Sofinnova Partners, explains more about the Maestro System that Moon Surgical has built along with its unique business model. Listen Now

MedCity News • PO Box 901 • New York, NY unsubscribe